NCT02391415已完成2 期
Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 416
- 试验地点
- 4
- 主要终点
- The difference between the VPM1002 and BCG vaccination groups in the incidence of grade 3 and 4 adverse drug reactions and IMP-related ipsilateral or generalised lymphadenopathy of 10mm or greater (diameter).
研究概览
简要总结
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas and persons at risk in non-endemic areas. The new vaccine should be at least as potent as the current strain and should be safer than BCG.
The preceding phase-IIa trial was the first investigation of VPM1002 in newborn infants in a high burden setting in South Africa. The vaccination of HIV-unexposed infants with VPM1002 indicated again safety, tolerability and immunogenicity sufficient to proceed in HIV-exposed infants.
The current study is a multiple site trial in South Africa to evaluate safety and immunogenicity in HIV-unexposed and -exposed newborn infants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- — 至 12 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The infant's mother must be aged 18 years or older at screening.
- •The infant's mother must be able and willing to comply with the study protocol, available and willing to allow her child to complete all the study assessments and must have signed an Informed Consent form that has been approved by all relevant Ethics Committee/s.
- •The infant's mother must not have any symptoms or signs of active TB as indicated by history of cough for more than two weeks, fever, weight loss, breathlessness, chest pain, blood in sputum, night sweats and loss of appetite
- •The infant's mother should not be planning to relocate from the research site area and should be reachable by phone during the whole study period i.e. for the 12 months on-study period as well as the 24 month structured medical surveillance period.
- •For HIV-unexposed group: The infant's mother must test negative for HIV-1 (ELISA 4th generation) within the period from 2 weeks prior to the infant's birth to vaccination of the infant with the investigational product.
- •For the HIV-exposed group: The infant's mother must test positive for HIV-1 (ELISA 4th generation) within the period from 2 weeks prior to the infant's birth to vaccination of the infant with the investigational product. The infant's mother must have enrolled for standard antiretroviral therapy (ART) at least 3 months before the participating infant's birth and must have a viral load at screening below 1000 copies/ml. The use of ART, including combination antiretroviral therapy (cART) and preventive mother to child transmission (PMTCT) must be documented. CD4+ T cell count and HIV viral load must be documented.
- •The infant's mother must test negative for Hepatitis B and syphilis serology at screening.
- •The infant's mother should have no history or evidence of diabetes mellitus.
- •No participation of the infant's mother in a clinical trial within 3 months prior to the birth of the participating infant. In addition, if breast-feeding, no participation in another clinical trial during the 12 months of the current study.
- •The infant's mother must have no known history of immunodeficiency, except for HIV.
- •Healthy male or female newborn infants aged 0 to 12 days.
- •Infants must have a birth weight of 2500 - 4200 g and an Apgar score of > 7 at 5 minutes or earlier.
- •No eczema or other significant skin lesion or infection at the intended injection site.
- •No routine BCG vaccination administered (as per vaccination record)
- •Infants must receive Oral Polio Vaccine as part of the routine South African Expanded Programme on Immunisation (EPI) Childhood Immunisation schedule, and must adhere to the subsequent EPI schedule for the entire study period, except for the BCG vaccination at birth.
- •No participation of the infant in another clinical trial before study vaccination and during the 12 months of the current study.
排除标准
- •Known presence of any person in the household of the mother and newborn infant, or any recent visitor to the household with recently diagnosed, active tuberculosis disease (within last 3 months).
- •Treatment of the mother with blood products in the 6 months prior to or during the birth of the participating infant.
- •For the HIV-unexposed group: Positive test for HIV-1 either during the current pregnancy or at screening.
- •For the HIV-exposed group: Negative test for HIV-1 either during the current pregnancy or at screening.
- •Presence of signs or symptoms of any reported acute infectious disease at the time of screening.
- •Any reported or suspected substance abuse.
- •History or evidence of any systemic disease on physical examination or any acute, chronic or intercurrent illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.
- •Note: Neonatal jaundice not considered clinically significant by the investigator is not an exclusion.
- •Fever within the period post birth and prior to dosing. For the purposes of this protocol, fever in the infant will be defined as an axillary body temperature > 38.0°C measured by digital thermometer on at least 2 occasions not less than 6 hours apart.
- •Hypothermia within the period post birth and prior to dosing. For the purposes of this protocol, hypothermia in the infant will be defined as an axillary body temperature < 36.0°C measured by digital thermometer on at least 2 occasions not less than 6 hours apart.
- •Clinically suspected newborn sepsis.
- •Any malignant condition.
- •Any severe congenital malformation.
- •Concomitant treatment with medication that may significantly affect immune function (e.g. systemic corticoids, immunosuppressive drugs) before study vaccination. Antibiotics given before study vaccination would further constitute exclusion.
- •Treatment of the infant with blood products.
研究组 & 干预措施
HIV-unexposed infants VPM1002
Experimental
HIV-unexposed infants vaccinated with VPM1002
干预措施: VPM1002 (Biological)
HIV-unexposed infants VPM1002(Hyg+)
Experimental
HIV-unexposed infants vaccinated with VPM1002(Hyg+)
干预措施: VPM1002(Hyg+) (Biological)
HIV-unexposed infants BCG
Active Comparator
HIV-unexposed infants vaccinated with BCG
干预措施: BCG (Biological)
HIV-exposed infants BCG
Active Comparator
HIV-exposed infants vaccinated with BCG
干预措施: BCG (Biological)
HIV-exposed infants VPM1002
Experimental
HIV-exposed infants vaccinated with VPM1002
干预措施: VPM1002 (Biological)
结局指标
主要结局
The difference between the VPM1002 and BCG vaccination groups in the incidence of grade 3 and 4 adverse drug reactions and IMP-related ipsilateral or generalised lymphadenopathy of 10mm or greater (diameter).
时间窗: up to 12 months
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South AfricaTuberculosisNCT01113281Vakzine Projekt Management GmbH24
已完成
2 期
Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South AfricaTuberculosisNCT01479972Vakzine Projekt Management GmbH48
已完成
2 期
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C DeficiencyProtein C DeficiencyNCT00157118Baxalta now part of Shire18
已完成
1 期
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male VolunteersHealthyTuberculosisNCT00749034Vakzine Projekt Management GmbH80
招募中
1 期
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.Solid TumorNCT06603844Corbus Pharmaceuticals Inc.156